366-79-0

Basic information

• Product Name: (4-FLUORO-BENZOYLAMINO)-ACETIC ACID
• Synonyms: 2-(4-Fluorobenzamido)acetic acid;4-Fluorohippuric acid;p-Fluorohippuric acid;2-[(4-fluorophenyl)carbonylamino]ethanoic acid;2-[[(4-fluorophenyl)-oxomethyl]amino]acetic acid;N-(4-fluorobenzoyl)glycine
• CAS NO: 366-79-0
• Molecular Formula: C₉H₈FNO₃
• Molecular Weight: 197.17
• Mol File: 366-79-0.mol
• Article Data: 18

Chemical Properties

• Melting Point: 173 °C
• Boiling Point: 427.7°Cat760mmHg
• Flash Point: 212.5°C
• Appearance: /
• Density: 1.358g/cm³
• Vapor Pressure: 4.45E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (4-FLUORO-BENZOYLAMINO)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-FLUORO-BENZOYLAMINO)-ACETIC ACID(366-79-0)
• EPA Substance Registry System: (4-FLUORO-BENZOYLAMINO)-ACETIC ACID(366-79-0)

Safety Data

• Hazardous Substances Data: 366-79-0(Hazardous Substances Data)

Usage

General Description

The chemical (4-Fluoro-Benzoylamino)-Acetic Acid is a compound with the molecular formula C9H8FNO3. It is a derivative of acetic acid and contains a fluoro-benzoylamino group. (4-FLUORO-BENZOYLAMINO)-ACETIC ACID has various potential applications in the pharmaceutical and chemical industries, including as a building block for the synthesis of new chemical compounds, as a pharmaceutical intermediate in the production of drugs, and as a reagent in organic chemical reactions. Its specific properties and uses are the subject of ongoing research and development.

InChI:InChI=1/C9H8FNO3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)/p-1

Upstream product

• 128062-25-9 N-(4-fluoro)benzoyl glycine ethyl ester 
• 456-22-4 4-Fluorobenzoic acid 
• 66134-67-6 p-fluorobenzoic acid succinimidyl ester 
• 56-40-6 glycine 
• 6000-44-8 sodium glycinate 
• 403-43-0 4-fluorobenzoyl chloride 
• 75507-68-5 flupirtine maleate 

Downstream Products

• 331719-20-1 4-(4-nitrobenzylidene)-2-(4-fluorophenyl)-5(4H)-oxazolone 

Relevant articles and documents

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Synthesis of Novel Benzamide- piperazine-sulfonamide Hybrids as Potential Anticancer Agents

The synthesis of a series of substituted hippuric acid (2-benzamidoacetic acid) derivatives containing arylsulfonylpiperazine nucleus (3a–j, 4a–j) is described. The compounds were synthesized by coupling hippuric/4-fluorohippuric acid with various arylsulfonylpiperazines using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDCI). The structures of all the new compounds were confirmed by IR, NMR and MS spectral data. All the synthesized compounds have been evaluated for their in vitro cytotoxicity towards five human cancer cell lines of different origins viz. HeLa (Cervical), A549 (Lung), A375 (Skin), MD-AMB-231(Breast) and T98G (brain) and their IC50 values were determined. Among the compounds tested, 3b, 3d, 3g, 4c and 4e displayed significant cytotoxic activity (IC50 = 24.2–38.2 μM). T98G was the most sensitive cell line towards the compounds studied followed by HeLa, A375, A549 and MD-AMB-231.

Synthesis and biological testing of (5Z)-2-aryl-5-arylmethylidene-3,5-dihydro-4H-imidazol-4-ones as antimitotic agents

Compounds interacting with cell protein tubulin and microtubules represent an important type of antimitotic agents. A series of tubulin-targeted 2-aryl-4-benzoyl-imidazoles were reported to possess high cytotoxicity, and so, we prepared a series of structural isomers of these to be evaluated as antimitotic agents. The synthesis of the novel (Z)-2-aryl-5-arylmethylidene-3,5-dihydro-4H-imidazol-4-ones involved coupling of substituted hippuric acids with aromatic aldehydes. Subsequent conversion of the resulting oxazolones to the corresponding imidazolones was carried out under microwave irradiation in the presence of urea and ammonium acetate. The cytotoxicity of the majority of the compounds to human epithelial carcinoma cancer cell line A549 was in the sub-micromolar range and was found to be more sensitive to the substituents on the 5-arylmethylidene fragment than on the 2-aryl ring in general. The cytotoxicities of the synthesized compounds were lower than those of the previously reported isomeric 2-aryl-4-benzoyl-imidazoles, and the basic structure–activity relationships in the isomeric pairs were different. Synthesized (5Z)-5-[(4-bromophenyl)methylidene]-2-(4-methylphenyl)-3,5-dihydro-4H-imidazol-4-one, which had the highest cytotoxicity (IC50?~?440?nM) in the series of novel compounds, had a definite cytostatic effect on the A549 cells, but its antiproliferative properties were not linked to action on the microtubules. This would be an interesting lead compound for additional investigation into the mechanism of cytostatic action, and further structural optimization.